In both DCM models, the treatment with 34 was remarkably associated with NF-κB nucleus entry inhibition and Nrf2 activation, promoting anti-inflammatory and antioxidant effects. This evidence concerns the gene NFE2L2 and familial dilated cardiomyopathy.